A new report by XploreMR studies the growth drivers, trends, restraints, and highlights of the global cutaneous fibrosis treatment market. Presenting exclusive insights into the market from 2018 to 2026, the report projects that the market will witness significant growth during the forecast period. Cutaneous fibrosis is a condition that occurs due to abnormal fibroblast activity that leads to Extracellular Matrix (ECM) with excess collagen. The accumulation of collagen and other ECM molecules under the skin could cause numerous skin diseases such as a hypertrophic scar, scleroderma, and keloids. To treat cutaneous fibrosis, drugs such as corticosteroids, immunoglobulins, and anti-fibrotic drugs are generally used. The growth of the market is primarily driven by the increasing incidence of various skin diseases associated with cutaneous fibrosis. Although no cure exists at present, the availability of effective drugs and the development of new medicines will continue to shape the market's growth trajectory.
High Incidence of Skin Diseases Creates Uptick in Demand for Treatment
The rising incidence of cutaneous fibrosis-associated conditions, such as scleroderma, Graft Versus Host Disease (GVHD), and keloids, among other conditions, is anticipated to create growth opportunities for the cutaneous fibrosis treatment. Since cutaneous fibrosis-associated diseases are more prevalent in the age groups above 40, the aging population across the world is anticipated to contribute to market growth. Moreover, studies and researches are being conducted to understand the condition, in order to provide effective treatments. These studies are bolstering in evaluating treatment options and epidemiology of the disease, which are further helping to understand the prognosis of the disease. With no permanent cure available, players in the market are striving to develop novel formulations to treat cutaneous fibrosis. Currently, immunotherapy drugs, anti-fibrotic drugs, corticosteroids, and immunoglobulins are being used to treat the cutaneous fibrosis, with immunotherapy drugs being the most prominent drug type. However, lack of awareness among the general population is likely to impede the growth to a certain extent.
Europe and Asia Pacific Market Flourishes as Skin Diseases Witness Surge
North America is forecasted to hold the lion's share in the cutaneous fibrosis treatment market, backed by increasing cases of skin scars due to the high number of surgical procedures performed in the U.S. Moreover, the high aging population coupled with the increasing incidence of skin-related disorders in Europe is expected to contribute to the growth of the region's market share in the global value. On the other hand, a high number of trauma injuries in the Asia Pacific are bestowing lucrative revenue opportunities to the players in the cutaneous fibrosis treatment market. The growth of the region is also attributed to the high number of skin diseases in India and China.